Credit Suisse Ag Revance Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 180,148 shares of RVNC stock, worth $462,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares

180,148

Previous 172,007 4.73%

Holding current value

$462,980

Previous $1.51 Million 41.36%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$4.65 - $9.31 $37,855 - $75,792	8,141 Added 4.73%	180,148 $886,000
Q4 2023 Feb 08, 2024	BUY	$5.81 - $11.2 $182,387 - $351,590	31,392 Added 22.32%	172,007 $1.51 Million
Q3 2023 Nov 13, 2023	SELL	$11.47 - $25.07 $18,042 - $39,435	-1,573 Reduced 1.11%	140,615 $1.61 Million
Q2 2023 Aug 11, 2023	BUY	$24.7 - $37.61 $82,547 - $125,692	3,342 Added 2.41%	142,188 $3.6 Million
Q1 2023 May 10, 2023	BUY	$18.36 - $35.27 $162,320 - $311,822	8,841 Added 6.8%	138,846 $4.47 Million
Q4 2022 Feb 13, 2023	BUY	$18.32 - $30.66 $600,016 - $1 Million	32,752 Added 33.68%	130,005 $2.4 Million
Q3 2022 Nov 10, 2022	BUY	$14.33 - $28.47 $91,368 - $181,524	6,376 Added 7.02%	97,253 $2.63 Million
Q2 2022 Aug 12, 2022	BUY	$11.52 - $20.4 $2,580 - $4,569	224 Added 0.25%	90,877 $1.26 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $70,241 - $115,421	5,683 Added 6.69%	90,653 $1.77 Million
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $13,531 - $30,266	-1,086 Reduced 1.26%	84,970 $1.39 Million
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $96,958 - $124,902	3,761 Added 4.57%	86,056 $2.4 Million
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $96,667 - $114,846	-3,607 Reduced 4.2%	82,295 $2.44 Million
Q1 2021 May 14, 2021	SELL	$24.03 - $29.97 $518,999 - $647,292	-21,598 Reduced 20.09%	85,902 $2.4 Million
Q4 2020 Feb 12, 2021	BUY	$23.41 - $28.34 $1.2 Million - $1.45 Million	51,109 Added 90.63%	107,500 $3.05 Million
Q3 2020 Nov 13, 2020	BUY	$23.23 - $34.3 $160,914 - $237,596	6,927 Added 14.0%	56,391 $1.42 Million
Q2 2020 Aug 12, 2020	SELL	$12.6 - $26.55 $126,957 - $267,517	-10,076 Reduced 16.92%	49,464 $1.21 Million
Q1 2020 May 13, 2020	BUY	$12.46 - $27.81 $305,618 - $682,123	24,528 Added 70.06%	59,540 $881,000
Q4 2019 Feb 12, 2020	BUY	$11.66 - $20.15 $92,895 - $160,535	7,967 Added 29.46%	35,012 $568,000
Q3 2019 Nov 12, 2019	SELL	$10.22 - $14.5 $20,051 - $28,449	-1,962 Reduced 6.76%	27,045 $352,000
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $57,383 - $83,305	5,378 Added 22.76%	29,007 $376,000
Q1 2019 May 14, 2019	BUY	$15.4 - $20.39 $59,274 - $78,481	3,849 Added 19.46%	23,629 $373,000
Q4 2018 Feb 13, 2019	BUY	$18.06 - $24.96 $44,463 - $61,451	2,462 Added 14.22%	19,780 $398,000
Q3 2018 Nov 13, 2018	SELL	$23.55 - $30.1 $176,413 - $225,479	-7,491 Reduced 30.19%	17,318 $431,000
Q2 2018 Aug 14, 2018	SELL	$27.45 - $33.35 $21,026 - $25,546	-766 Reduced 3.0%	24,809 $682,000
Q1 2018 May 15, 2018	SELL	$29.15 - $37.4 $72,612 - $93,163	-2,491 Reduced 8.88%	25,575 $788,000
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $90,663 - $134,055	3,693 Added 15.15%	28,066 $1 Million
Q3 2017 Nov 14, 2017	BUY	$22.55 - $28.1 $265,345 - $330,652	11,767 Added 93.34%	24,373 $670,000
Q2 2017 Aug 14, 2017	BUY	N/A	12,606	12,606 $332,000

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account